We investigated the role of polymorphism of the vitamin D receptor (VDR) gene in HLA-matched sibling BMT for polymorphisms previously associated with human disease pathology. In intron 8 of the VDR gene, the B and A alleles of the BsmI and ApaI RFLPs were found to associate with reduced aGVHD when present in the patient's genotype. Logistic regression analysis demonstrated that patient VDR genotype, along with previously identified IL-10 ؊1064 and IFN-␥ genotype to be risk factors for severe acute GVHD. The A allele also associates with increased likelihood of death when present in the donor genotype (AA vs Aa or aa, hazard ratio 2.03, P = 0.0232). In patients who received increased prophylaxis with multi-agent therapy, patients whose graft was from a donor with an AA genotype had a substantially worse survival than patients whose graft was from a donor with a non-AA genotype (hazard ratio 12.93, P Ͻ 0.0001). and poly-A polymorphisms are in linkage disequilibrium with each other. It is proposed that these polymorphisms exert their effects through enhanced transcription of the VDR gene or through altered mRNA stability.
and poly-A polymorphisms are in linkage disequilibrium with each other. It is proposed that these polymorphisms exert their effects through enhanced transcription of the VDR gene or through altered mRNA stability. 5, 6 The role of vitamin D3 and of the VDR in bone metabolism and turnover is well established. Homozygosity for the closely linked bb and aa genotypes of the BsmI and ApaI RFLPs in intron 8 is associated with increased femoral and vertebral bone density. 3, 4, 7 Reduced bone loss associated with liver transplantation is less frequent in transplant patients who possess the BsmI and ApaI aa and bb genotypes for VDR. 8 Polymorphism at the ATG initiation codon (FokI site) has been associated with genetic determination of final height in Japanese subjects, with heterozygotes at this locus achieving a greater final height than homozygotes for either allele, 1 and with heritable variation in bone mineral density. 9 Polymorphism at both the FokI and TaqI sites has been associated with variation in intervertebral disc degeneration in males. 10 The VDR is also found in both normal and neoplastic haemopoietic cells. It is constitutively expressed in monocytes, and in both B and T lymphocytes following activation. Polymorphism of the VDR gene has been associated with diseases of immune dysfunction. Variation in severity of disease phenotype is seen in common variable immune deficiency, where the VDR ApaI-TaqI AT haplotype at intron 8 and exon 9 is associated with more severe clinical phenotype. 11 VDR gene polymorphism has also been linked with susceptibility to infectious disease. Polymorphism at the TaqI site has been associated with localised early onset periodontal disease 3 and with susceptibility to leprous and tubercular subtypes of leprosy. 12 The VDR has an important role in the development of the immune system. In knockout mice, loss of the VDR gene promotes T helper type 2 (Th2) differentiation or suppresses Th1 differentiation, and reduces macrophage colony forming capacity in vitro. 13 These results suggest that the VDR may affect development of Th1/2 responses during immune reconstitution post allogeneic bone marrow transplantation (BMT) and therefore influence the development of graft-versus-host-disease (GVHD), an alloimmune complication involving both dysregulated Th1 response and macrophage activation. 14, 15 The use of a vitamin D analogue, MC 1288, has recently been shown to prevent acute GVHD (aGVHD) in a rat BMT model. 16 Recently, we have
Bone Marrow Transplantation investigated a number of cytokine gene polymorphisms and have shown an association of recipient genetic influence upon BMT complications such as GVHD and mortality following HLA-matched sibling BMT. [17] [18] [19] We investigated the relationship between VDR gene polymorphism and clinical outcomes in HLA-matched sibling BMT. Recipient and donor genotypes correlated with occurrence and severity of aGVHD and chronic GVHD (cGVHD) and survival. We report that associations exist between VDR gene polymorphism in recipients and aGVHD, and also between VDR gene polymorphism in donors and survival.
Materials and methods

Patients and donors
Stored DNA was available on 88 transplant recipients, and 80 of their sibling donors, transplanted between 1983 and 1998. All recipients were transplanted for haemopoietic malignancy with acute leukaemia and chronic myeloid leukaemia being the most common underlying diagnoses. (AML 36; ALL 19; CML 21; NHL 2; MDS 2; MM 2; HD 2).
Fifty-one of the 88 patients were in a lower risk of relapse group, either in CR1 of acute leukaemia (excluding Philadelphia-positive or secondary leukaemias) or in CP1 of CML. Median recipient age was 29 years and that of donors was 28 years. Fifty-five recipients and 43 donors were male.
HLA-matching had been performed serologically for HLA-A and -B antigens and by high resolution molecular typing for HLA-DRB1. Conditioning was by protocol for disease and stage; a total of 68 patients was conditioned with fractionated total body irradiation (TBI) (total 1200 cGy) and either cyclophosphamide (60 mg/kg ϫ 2) (pre-1990; n = 43) or melphalan (3 mg/kg) (post 1989; n = 25). TBI was avoided for patients who had received prior radiotherapy or had CML. Fifteen patients received busulphan (4 mg/kg ϫ 4) in combination with cyclophosphamide (n = 9) or melphalan (n = 6). A patient with AML in CR2 received melphalan and etoposide (1800 mg), and two patients with HD received melphalan, etoposide and BCNU (300 mg/m 2 ). One hypoplastic MDS patient received cyclophosphamide alone, and one aplastic anaemia patient received melphalan alone.
All grafts were T cell replete. GVHD prophylaxis consisted of 3 mg/kg cyclosporin A (CyA), either alone (n = 61) or together with other drugs (n = 27) for patients at higher risk of GVHD (determined by skin explant model 20 or by advanced recipient age and/or multiparous female donor with male recipient). Extra immunosuppression consisted of methotrexate 21 (MTX) in 17 patients; corticosteroids (CS) in four; anti-thymocyte globulin (ATG) in four; MTX and ATG in one; CS and ATG in one.
aGVHD was diagnosed using conventional criteria, 22 and was deemed analysable in those who survived more than 30 days from BMT or who died prior to this with significant aGVHD, defined as that of grade II or above (n = 84). Fourteen patients developed no aGVHD, 31 patients grade I, 22 patients grade II, 11 patients grade III, and six patients grade IV; grades III and IV of aGVHD were considered severe. To avoid confounding affects of in vivo T cell depletion those patients who received ATG were excluded from subgroup analysis of GVHD (n = 78), and a further data analysis was performed on those who received CyA alone (n = 57). Chronic GVHD was assessable in 65 patients who survived beyond +100 days using established criteria. 23 Twenty-five of 65 patients developed cGVHD. Causes of death included disease relapse (14) , GVHD (six), infections (11, including CMV two), graft failure (one), others six (including ARDS one, haemorrhage one).
VDR genotyping
All genotypes were determined whilst blinded to clinical outcomes. DNA was prepared from archival frozen material using conventional techniques (SDS lysis, proteinase K digestion, phenol/chloroform extraction and ethanol precipitation). PCR for the relevant regions of the VDR gene and restriction enzyme digestion of the products were done essentially as described for the FokI, 1 BsmI,
and TaqI. 3 RFLPs. All restriction digests were done with a five-fold excess of enzyme to avoid partial digest products. Restriction digest products were separated by agarose gel electrophoresis at either 2% (FokI, ApaI, TaqI) or 1% (BsmI) using NuSieve GTG wide-range agarose (FMC BioProducts, Rockland, ME, USA), with detection by ethidium bromide staining and UV transillumination. PCR for the Tru9I RFLP was done as described 4 with detection by SSCP on 12% polyacrylamide gels (acrylamide:bis-acrylamide = 37.5:1). The poly-A tract region was amplified as described 5 with the various alleles ('short' alleles (S) and 'long' alleles (L) ) identified by separation on 10% polyacrylamide gels (acrylamide:bis-acrylamide = 19:1) following restriction of the product with the enzyme HpaII to shift the polymorphic portion of the PCR product into a more favourable gel register for size discrimination. Visualisation of all PCR products on acrylamide gels was by silver staining. All alleles were named as per the original reports described above. Chromosomal gene locations were obtained from the NCBI 'locuslink' Webpage (www.ncbi.nih.gov/LocusLink/) (January 2000).
Statistical analysis
Estimates of genetic linkage disequilibrium were made from 2 calculations as described 24 with a coefficient of 0.5 being unlinked (in equilibrium) and a coefficient of 1.0 being in full linkage disequilibrium. All quoted disequilibrium estimates were statistically significant (P Ͻ 0.01).
Univariable analysis of GVHD was in contingency tables by Fisher's exact test (two-tailed) and of survival in Kaplan-Meier plots by log rank test ( 2 ) using GraphPad Prism2 software. Logistic analysis of GVHD was by forward stepwise binomial logistic regression and of survival data by Cox proportional hazards modelling using Statistica 2 software. Values of less than 0.05 were regarded as statistically significant, and those between 0.05 and 0.1 as suggestive of a trend.
Results
Allele frequencies and haplotypes
The The FokI RFLP and the Tru9I RFLP were not in significant linkage with the other RFLPs in our study. To simplify discussion all patient /donor association studies refer to the ApaI polymorphism, but were found to apply equally to the ApaI-BsmI haplotype.
Association of patient genotype with clinical outcome
The ApaI a allele associated with severe aGVHD when present in the patients' genotype. Only one of 21 recipients homozygous for the A allele (AA) (associated with low VDR activity) developed severe (grade III-IV) aGVHD, while 16 of 63 recipients who were homozygous (aa) or heterozygous (Aa) for the a allele developed severe aGVHD (P = 0.058). A similar trend was demonstrated in patients not receiving ATG prophylaxis: one of 19 transplant recipients who were AA homozygotes developed severe aGVHD, while 15 of 59 transplant recipients with Aa or aa genotypes developed severe aGVHD (P = 0.099) ( Table 1 ). The same trend was seen if the analysis was restricted to those patients who had received CyA alone as prophylaxis, one of 17 recipients possessing an AA genotype developed severe aGVHD, whereas 12 of 40 recipients who were Aa heterozygotes or aa homozygotes developed severe aGVHD (P = 0.082) ( Table 1) .
Association of VDR genotype with aGVHD was also examined after adjusting for other variables known to associate with occurrence of aGVHD by logistic regression analysis. Clinical variables included in the analysis were patient and donor age, CMV status, and gender mismatch (female donor into male recipient). Genotypic variables for previously indicated risk factors associated with aGVHD included TNFd microsatellite (homozygous d3/d3), IL-10 Ϫ1064 microsatellite (high repeat No.), IFN-␥ intron 1 microsatellite (homozygous 3,3), and IL-1Ra VNTR (allele 2) (all genotypic risk factors are described in Ref. 19) .
Combining all the clinical and biological risk factors, three were found to remain significantly associated with severe aGVHD. These were IL-10 Ϫ1064 (high repeat No.)genotype, IFN-␥ intron 1 microsatellite (homozygous 3,3) genotype and VDR genotype. Removing these terms from the logistic model would result in highly significant changes (Table 2) . Other possible risk factors with strong trends towards association with severe aGVHD in this multivariable analysis were IL-1Ra genotype (P = 0.068) but not CMV status (recipient or donor), underlying disease, patient or donor age or GVHD prophylaxis (which had been targeted at those felt to be at high risk).
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Accurate quantification of relative odds ratios for these factors was not possible with the number of subjects within the study.
Polymorphism at the nearby TaqI site and the linked poly-A region are in linkage disequilibrium with the ApaI polymorphism. Possession of the linked alleles (t at the TaqI locus and S at the Poly-A locus) showed weak trends towards association with GVHD, but did not associate significantly so, nor did polymorphism at the ATG codon (FokI site, exon 2) or the Tru9I RFLP. Polymorphism in the patient genome at any of the RFLPs tested did not associate with cGVHD. Recipient VDR genotype also showed no association with overall survival, whether tested in the entire group or by prophylaxis regimen.
Association of donor genotype with clinical outcome
Donor VDR AA genotype did not show significant association with aGVHD. However, there was a trend in those patients whose donors were homozygous for the high VDR activity genotype aa to develop more severe aGVHD, whether in the overall cohort or when examined by prophylaxis. Logistic regression analysis confirmed that donor VDR aa genotype exhibited a strong trend towards being a risk factor for severe aGVHD when corrected for the variables described above (P = 0.065).
Patients receiving marrow with a VDR aa genotype showed an increased likelihood of developing cGVHD. After logistic regression analysis for other known risk factors for cGVHD (age, gender, gender mismatch (recipient male/donor female) and IL-6 Ϫ174 genotype, 18 donor VDR genotype continued to show a strong trend towards association with cGVHD (Table 3) .
Donor possession of the ApaI a allele was associated with improved likelihood of patient survival. Patients who received bone marrow from a donor with an AA genotype were twice as likely to die as patients who received marrow Table 3 Logistic regression analysis of the association of donor VDR genotype with chronic GVHD Table 2 legend. NS = not significant (term was not entered into the model). from a donor with an Aa or aa genotype (Kaplan-Meier hazard ratio 2.027; P = 0.0232) (Figure 1 ). This difference in survival was not seen in those patients receiving CyA alone prophylaxis (P = 0.83). Among those who received increased multi-agent prophylaxis patients whose graft was from a donor of AA genotype had a substantially worse survival than patients whose graft was from a donor of Aa or aa genotype (HR 12.93; P Ͻ 0.0001) (Figure 2 ). Cox regression analysis of other variables to adjust for factors known to influence survival was done and included patient age, CMV status and gender mismatch (female donor into male patient). In this analysis gender mismatch transplant (female donor/male patient) was the most significant indicator of survival (P = 0.048), with donor VDR genotype still showing a trend towards significant association with overall survival after correction for these known risk factors (VDR genotype P = 0.093). If occurrence of aGVHD is included in this multivariant model, the analysis indicates that aGVHD is a significant outcome indicator (P = 0.002, significance of the change if this term is removed from the model P = 0.003), with VDR genotype showing strengthened association with outcome in these conditions (P = 0.054). CMV status showed no association with survival in this study, nor did underlying disease. Accurate multivariable quantification of relative hazard ratios was not possible within the power of the study. The FokI, Tru9I and TaqI RFLPs were not associated with survival when present in the donor genotype (data not shown).
Discussion
We have identified an association between common polymorphisms of the VDR gene and the occurrence of complications following HLA-matched sibling BMT. We identified two closely linked RFLPs as being associated with aGVHD severity when present in the patients' genotype (the b allele at the BsmI site and the a allele at the ApaI site of intron 8 of the VDR gene). The same two alleles are associated with high bone mineral density in studies on normal subjects. 2, 7 The A allele at this locus is found to be over-represented in a population of patients with severe common variable immune deficiency 11 who exhibit a particular clinical phenotype suggesting that VDR gene polymorphism at this locus may have a wide range of biological effects. Analysis of recipient VDR genotype may be useful in predicting a patient's likelihood of developing aGVHD, allowing appropriate adjustment of GVHD prophylaxis.
A number of gene polymorphisms have been associated with severity of aGVHD including those for the pro-and anti-inflammatory cytokines such as TNF␣, IL-10, IL-6, IFN-␥ and IL-1Ra. [17] [18] [19] Determination of a number of these polymorphisms may form the basis of an individual patient risk assessment for risk of transplant-related complications prior to transplantation. The assessment of non-cytokine gene polymorphisms such as the VDR polymorphisms discussed here might improve the power of such measurements to predict patients at risk from severe aGVHD.
Our observation of an association between donor VDR genotype and outcome suggests that the effects of the VDR genotype on the patient's performance are also exerted by the donor bone marrow following reconstitution. Survival was substantially lower among those whose graft had VDR ApaI AA genotype; this effect was demonstrated in those patients who were given increased GVHD prophylaxis, rather than those who received CyA alone. Multivariable analysis confirmed that donor VDR genotype was associated with survival, but that increased prophylaxis alone was not; however, donor VDR genotype stratified by prophylaxis regimen was independently associated with overall survival.
Among those patients who received marrow from donors with AA genotype the leading causes of death were relapse, infection and interstitial pneumonitis. The AA genotype in the recipients is associated with less severe aGVHD, while its presence in the donor appears to lead to a reduced protective effect against infection and relapse (graft-versusleukaemia effect), most notably in those treated with the more intense immunosuppressive therapies.
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Most studies on VDR gene polymorphism have studied Caucasian and Hispanic populations, which have similar allele frequencies to those seen in our study. A study on a Chinese population found that the A allele of the ApaI polymorphism is only found in 5% of that population. 25 VDR genotype may therefore represent a transplant risk factor whose importance varies with the population involved.
Clearly, these studies need to be confirmed in other patient and donor populations, ideally in a prospective manner. The identification of a donor risk genotype might indicate patients requiring differential application of prophylaxis (eg targeted addition of increased prophylaxis only for patients whose donors were of Aa/aa genotype), and where this were not possible to increase vigilance for infection and relapse. If the same association was demonstrated for the genotype of unrelated donors, then VDR gene analysis could be of value in donor selection by avoiding donors with a high-risk genotype.
The associations demonstrated of VDR genotype with GVHD and survival further extend the biological and clinical spectrum of action of this multi-faceted vitamin and its receptor. In summary, this is the first account of the role of VDR gene polymorphisms in complications of allogeneic BMT and leads the way forward for future studies of VDR in the biology of transplantation.
